A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Neoplasms|Colon Cancer|Colonic Cancer|Colon Neoplasms|Lung Cancer|Melanoma|Kidney Cancer
Interventions: DRUG: AZD6244|DRUG: Dacarbazine|DRUG: Erlotinib|DRUG: Docetaxel|DRUG: Temsirolimus
Sponsor: AstraZeneca